These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26311235)

  • 1. Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study.
    Senanayake VK; Jin W; Mochizuki A; Chitou B; Goodenowe DB
    BMC Neurol; 2015 Aug; 15():154. PubMed ID: 26311235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
    Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
    Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis.
    Malhotra S; Fissolo N; Tintoré M; Wing AC; Castilló J; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroinflammation; 2015 Mar; 12():48. PubMed ID: 25879961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
    Wood PL; Smith T; Lane N; Khan MA; Ehrmantraut G; Goodenowe DB
    Lipids Health Dis; 2011 Dec; 10():227. PubMed ID: 22142382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
    PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis.
    Takewaki D; Suda W; Sato W; Takayasu L; Kumar N; Kimura K; Kaga N; Mizuno T; Miyake S; Hattori M; Yamamura T
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22402-22412. PubMed ID: 32839304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
    Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
    Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
    Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns.
    Salehi Z; Doosti R; Beheshti M; Janzamin E; Sahraian MA; Izad M
    PLoS One; 2016; 11(7):e0159565. PubMed ID: 27467597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes.
    Jalonen TO; Pulkkinen K; Ukkonen M; Saarela M; Elovaara I
    J Neurol; 2002 May; 249(5):576-83. PubMed ID: 12021948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis.
    Braidy N; Lim CK; Grant R; Brew BJ; Guillemin GJ
    Brain Res; 2013 Nov; 1537():267-72. PubMed ID: 23973746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
    Malhotra S; Castilló J; Bustamante M; Vidal-Jordana A; Castro Z; Montalban X; Comabella M
    Mult Scler; 2013 Apr; 19(5):524-31. PubMed ID: 22933622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
    de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
    Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Vistbakka J; Elovaara I; Lehtimäki T; Hagman S
    Mult Scler; 2017 Mar; 23(3):403-412. PubMed ID: 27246141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS.
    Tsaktanis T; Beyer T; Nirschl L; Linnerbauer M; Grummel V; Bussas M; Tjon E; Mühlau M; Korn T; Hemmer B; Quintana FJ; Rothhammer V
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33361385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.